These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain. García-Castillo M; García-Fernández S; Gómez-Gil R; Pitart C; Oviaño M; Gracia-Ahufinger I; Díaz-Regañón J; Tato M; Cantón R; Int J Antimicrob Agents; 2018 Mar; 51(3):511-515. PubMed ID: 29371104 [TBL] [Abstract][Full Text] [Related]
23. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations. Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307 [TBL] [Abstract][Full Text] [Related]
24. Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016. Sader HS; Castanheira M; Shortridge D; Mendes RE; Flamm RK Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827415 [TBL] [Abstract][Full Text] [Related]
25. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. Gaibani P; Campoli C; Lewis RE; Volpe SL; Scaltriti E; Giannella M; Pongolini S; Berlingeri A; Cristini F; Bartoletti M; Tedeschi S; Ambretti S J Antimicrob Chemother; 2018 Jun; 73(6):1525-1529. PubMed ID: 29566151 [TBL] [Abstract][Full Text] [Related]
26. Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. Shields RK; Potoski BA; Haidar G; Hao B; Doi Y; Chen L; Press EG; Kreiswirth BN; Clancy CJ; Nguyen MH Clin Infect Dis; 2016 Dec; 63(12):1615-1618. PubMed ID: 27624958 [TBL] [Abstract][Full Text] [Related]
27. Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections. Shields RK; Nguyen MH; Chen L; Press EG; Kreiswirth BN; Clancy CJ Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29507064 [TBL] [Abstract][Full Text] [Related]
28. Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model. Barber KE; Pogue JM; Warnock HD; Bonomo RA; Kaye KS J Antimicrob Chemother; 2018 Sep; 73(9):2405-2410. PubMed ID: 29939267 [TBL] [Abstract][Full Text] [Related]
29. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421 [TBL] [Abstract][Full Text] [Related]
31. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067 [TBL] [Abstract][Full Text] [Related]
32. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16. Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202 [TBL] [Abstract][Full Text] [Related]
33. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia. Hakeam HA; Alsahli H; Albabtain L; Alassaf S; Al Duhailib Z; Althawadi S Int J Infect Dis; 2021 Aug; 109():1-7. PubMed ID: 34091006 [TBL] [Abstract][Full Text] [Related]
34. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae. Santevecchi BA; Smith TT; MacVane SH Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227 [TBL] [Abstract][Full Text] [Related]
35. KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues. Antonelli A; Giani T; Di Pilato V; Riccobono E; Perriello G; Mencacci A; Rossolini GM J Antimicrob Chemother; 2019 Aug; 74(8):2464-2466. PubMed ID: 31318973 [No Abstract] [Full Text] [Related]
36. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541 [TBL] [Abstract][Full Text] [Related]
37. Assessment of the Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764 [No Abstract] [Full Text] [Related]
38. In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15. Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF J Antimicrob Chemother; 2018 Oct; 73(10):2782-2788. PubMed ID: 30010894 [TBL] [Abstract][Full Text] [Related]
39. Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): activity of ceftazidime/avibactam against Enterobacterales isolated from urine. Giani T; Antonelli A; Sennati S; Di Pilato V; Chiarelli A; Cannatelli A; Gatsch C; Luzzaro F; Spanu T; Stefani S; Rossolini GM J Antimicrob Chemother; 2020 Apr; 75(4):979-983. PubMed ID: 31958125 [TBL] [Abstract][Full Text] [Related]
40. Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia. Wu G; Abraham T; Lee S Clin Infect Dis; 2016 Oct; 63(8):1147-8. PubMed ID: 27432841 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]